Chronic inflammation is a common factor in obesity, diabetes mellitus, and the
complications of diabetes, including diabetic wounds. These ulcers are
characterized by persistent lesions that are challenging to heal, significantly
decreasing patients’ quality of life and imposing a substantial
financial burden on society. MMP are zinc endopeptidases that play a role in
wound healing in response to various stimuli, including diabetes mellitus. MMP
levels fluctuate throughout the wound healing process in diabetic
patients' serum, skin tissues, and wound fluid, indicating their
potential as biomarkers for diabetic foot ulcers. Targeting MMP has emerged as a
promising strategy for treating diabetic wounds, as these enzymes are involved
in critical biological processes related to wound healing, including
extracellular matrix secretion, angiogenesis, granulation tissue formation,
collagen growth, re-epithelization, inflammatory response, and oxidative
stress.